WO2011160732A1 - Variantes de la néprilysine humaine de type protéase - Google Patents

Variantes de la néprilysine humaine de type protéase Download PDF

Info

Publication number
WO2011160732A1
WO2011160732A1 PCT/EP2010/070615 EP2010070615W WO2011160732A1 WO 2011160732 A1 WO2011160732 A1 WO 2011160732A1 EP 2010070615 W EP2010070615 W EP 2010070615W WO 2011160732 A1 WO2011160732 A1 WO 2011160732A1
Authority
WO
WIPO (PCT)
Prior art keywords
neprilysin
polypeptide
peptide
seq
hsa
Prior art date
Application number
PCT/EP2010/070615
Other languages
English (en)
Inventor
Carl Innes Webster
Lutz Ulrich Jochen Wilhelm Jermutus
Jorg Birkenfeld
Andrea Eicker
Per-Ola Freskgard
Claudia Gotzberger-Schad
Joanna Grudzinska
Ulrich Haupts
Josi Innig
Christoph Mahlert
Andreas Scheidig
Michael Strerath
Jan Tebbe
Johan Per Wallin
Nina Wobst
Original Assignee
Medimmune, Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/039392 external-priority patent/WO2010148413A2/fr
Application filed by Medimmune, Llc. filed Critical Medimmune, Llc.
Priority to PCT/EP2011/060385 priority Critical patent/WO2011161127A1/fr
Publication of WO2011160732A1 publication Critical patent/WO2011160732A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6494—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des polypeptides comprenant des variantes de type protéase de la néprilysine humaine de type sauvage présentant une spécificité et/ou une activité altérées. En particulier, la présente invention concerne des polypeptides comprenant des variantes de type protéase dérivées de néprilysine humaine présentant une spécificité et/ou une activité améliorée contre certains substrats, en particulier contre le bêta-amyloïde.
PCT/EP2010/070615 2010-06-21 2010-12-22 Variantes de la néprilysine humaine de type protéase WO2011160732A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2011/060385 WO2011161127A1 (fr) 2010-06-21 2011-06-21 Variants de protéase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2010/039392 WO2010148413A2 (fr) 2009-06-19 2010-06-21 Variantes de protéase
USPCT/US2010/039392 2010-06-21

Publications (1)

Publication Number Publication Date
WO2011160732A1 true WO2011160732A1 (fr) 2011-12-29

Family

ID=43880972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/070615 WO2011160732A1 (fr) 2010-06-21 2010-12-22 Variantes de la néprilysine humaine de type protéase

Country Status (1)

Country Link
WO (1) WO2011160732A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2832854A1 (fr) * 2013-08-02 2015-02-04 F. Hoffmann-La Roche AG Méthode d'amélioration de l'expression d'une polypeptide par la fusion C-terminale avec neprilysin humaine
WO2015014884A1 (fr) * 2013-08-02 2015-02-05 F. Hoffmann-La Roche Ag Protéine de fusion thérapeutique

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US6204023B1 (en) 1985-11-01 2001-03-20 Xoma Ltd. Modular assembly of antibody genes, antibodies prepared thereby and use
US20030083277A1 (en) 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
WO2005123119A2 (fr) 2004-06-10 2005-12-29 Catalyst Biosciences, Inc. Administration d'endopeptidase neutre afin de traiter les maladies intestinales inflammatoires
WO2007040437A1 (fr) 2005-10-03 2007-04-12 Astrazeneca Ab Protéines de fusion ayant une demi-vie modulee dans du plasma
WO2008118093A1 (fr) 2007-03-28 2008-10-02 Astrazeneca Ab Protéine de fusion pouvant dégrader le peptide bêta-amyloïde
WO2010148413A2 (fr) * 2009-06-19 2010-12-23 Medimmune, Llc Variantes de protéase

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US6204023B1 (en) 1985-11-01 2001-03-20 Xoma Ltd. Modular assembly of antibody genes, antibodies prepared thereby and use
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US20030083277A1 (en) 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
WO2005123119A2 (fr) 2004-06-10 2005-12-29 Catalyst Biosciences, Inc. Administration d'endopeptidase neutre afin de traiter les maladies intestinales inflammatoires
WO2007040437A1 (fr) 2005-10-03 2007-04-12 Astrazeneca Ab Protéines de fusion ayant une demi-vie modulee dans du plasma
WO2008118093A1 (fr) 2007-03-28 2008-10-02 Astrazeneca Ab Protéine de fusion pouvant dégrader le peptide bêta-amyloïde
WO2010148413A2 (fr) * 2009-06-19 2010-12-23 Medimmune, Llc Variantes de protéase

Non-Patent Citations (49)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", 1989, GREENE PUBLISHING ASSOCIATES
"Current Protocols in Molecular Biology", 2002, JOHN WILEY & SONS
"Current Protocols in Protein Science", 1996, JOHN WILEY & SONS, pages: 9.4,9.5
"Current Protocols in Protein Science", 1999, JOHN WILEY & SONS
"Molecular Cloning; A Laboratory Manual", 1989, COLD SPRING HARBOR
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO., pages: 1435 - 1712
BARD ET AL., NATURE MEDICINE, vol. 6, no. 8, 2000, pages 916 - 919
BARROS ET AL., BIOL. CHEM., vol. 388, 2007, pages 447 - 455
BEAUMONT ET AL., J. BIOL. CHEM., vol. 266, 1991, pages 214 - 220
BEAUMONT ET AL., J. BIOL. CHEM., vol. 267, 1992, pages 2138 - 41
BORCHELT D. R. ET AL., NEURON, vol. 17, 1996, pages 1005 - 1013
CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167
CITRON M. ET AL., NEUROBIOL. DIS., vol. 5, 1998, pages 107 - 116
DAVIS ET AL., BIOCHEM. INTL., vol. 10, 1985, pages 394 - 414
DEMATTOS, PNAS, vol. 98, 2001, pages 8850 - 8855
DION ET AL., FEBS LETT., vol. 411, 1997, pages 140 - 144
DUFF K. ET AL., NATURE, vol. 383, 1996, pages 710 - 713
ERICKSON ET AL.: "The Proteins", vol. 2, 1976, pages: 257 - 527
FINN ET AL.: "The Proteins", vol. 2, 1976, pages: 105 - 253
GLABE, C., NAT. MED., vol. 6, 2000, pages 133 - 134
GOEDDEL: "Methods in Enzymology", vol. 185, 1990, ACADEMIC PRESS, article "Gene Expression Technology"
GRAY, W., MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 288, 2008, pages 52 - 62
GUAN HANJUN ET AL: "Peripherally Expressed Neprilysin Reduces Brain Amyloid Burden: A Novel Approach for Treating Alzheimer's Disease", JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, vol. 87, no. 6, 1 May 2009 (2009-05-01), pages 1462 - 1473, XP002589911, ISSN: 0360-4012 *
HAMA EMI ET AL: "Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid beta peptide clearance in primary neurons", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, vol. 279, no. 29, 16 July 2004 (2004-07-16), pages 30259 - 30264, XP002523061, ISSN: 0021-9258, [retrieved on 20040420], DOI: DOI:10.1074/JBC.M401891200 *
KIM ET AL., J. BIOL. CHEM., vol. 267, 1992, pages 12330 - 35
KLAPDOR ET AL.: "A low cost method to analyze footprint patterns", J. NEUROSCI. METHODS, vol. 75, 1997, pages 49 54
LEISSRING ET AL., JBC., vol. 278, 2003, pages 37314 - 37320
LU B. ET AL., ANN. N.Y. ACAD. SCI., vol. 780, 1996, pages 156 - 163
LU B. ET AL., J. EXP. MED., vol. 181, 1995, pages 2271 - 2275
MARIE-CLAIRE, PROTEINS, vol. 39, 2000, pages 365 - 371
MATSUOKA ET AL., J. NEUROSCIENCE, vol. 23, 2003, pages 29 - 33
MERRIFIELD, J. AM. CHEM. SOC., vol. 85, 1963, pages 2149
MERRIFIELD: "Chem. Polypeptides", 1973, pages: 335 - 61
OEFNER ET AL., J. MOL. BIOL., vol. 296, 2000, pages 341 - 9
PONS, J. ET AL., CURRENT OPINION IN INVESTIGATIONAL DRUGS, vol. 5, 2004, pages 957 - 962
R. J. KAUFMAN; P. A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621
RADEMAKER M.T.; RICHARDS A.M., CLINICAL SCIENCE, vol. 108, 2005, pages 23 - 36
REID IAN A.: "Basic and Clinical Pharmacology", 1998, THE MCGRAW-HILL COMPANIES, article "Vasoactive Peptides"
ROQUES B. P. ET AL., PHARMACOL. REV., vol. 45, 1993, pages 87 - 146
SAHLI ET AL., HELV.CHIM.ACTA., vol. 88, 2005, pages 731
SARRET; KITABGI: "Encyclopedia of Neuroscience", 2009, pages: 1021 - 1034
SCHEUNER D. ET AL., NAT. MED., vol. 2, 1996, pages 864 - 870
SELKOE, D. J., NATURE, vol. 399, 1999, pages A23 - A31
SHIROTANI K ET AL: "Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 15 JUN 2001 LNKD- PUBMED:11278416, vol. 276, no. 24, 15 June 2001 (2001-06-15), pages 21895 - 21901, XP002634357, ISSN: 0021-9258 *
SOTO, C.; CASTANO, M., BIOCHEM. J., vol. 314, 1996, pages 701 - 707
STEWART; YOUNG, SOLID PHASE PEPTIDE SYNTHESIS, 1969
URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220
VASSAR, R. ET AL., SCIENCE, vol. 286, 1999, pages 735 - 41
YOUNKIN S. G., ANN. NEUROL., vol. 37, 1995, pages 287 - 288

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2832854A1 (fr) * 2013-08-02 2015-02-04 F. Hoffmann-La Roche AG Méthode d'amélioration de l'expression d'une polypeptide par la fusion C-terminale avec neprilysin humaine
WO2015014884A1 (fr) * 2013-08-02 2015-02-05 F. Hoffmann-La Roche Ag Protéine de fusion thérapeutique
CN105431203A (zh) * 2013-08-02 2016-03-23 豪夫迈·罗氏有限公司 治疗性融合蛋白

Similar Documents

Publication Publication Date Title
WO2011161127A1 (fr) Variants de protéase
US20210277378A1 (en) Coagulation factor ix compositions and methods of making and using same
US20080274096A1 (en) Fusion Proteins Having a Modulated Half-Life in Plasma
AU2008230177B2 (en) Fusion protein capable of degrading amyloid beta peptide
AU2005235635B2 (en) Bone delivery conjugates and method of using same to target proteins to bone
US20120237496A1 (en) Protease variants
WO2011160732A1 (fr) Variantes de la néprilysine humaine de type protéase
CN116710122A (zh) Enpp1缺乏症和abcc6缺乏症的治疗

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10809151

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10809151

Country of ref document: EP

Kind code of ref document: A1